Siemens Healthineers stock: RBC lifts target to EUR 48

Published on 10/21/2026 at 16:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q4 results are set for November 5, 2026. Siemens Healthineers stock costs EUR 41.62 on October 21, 2026, plus 0.43 percent versus the Xetra close.

RBC target and reporting date

RBC raised its Siemens Healthineers target to EUR 48.00 on October 15, 2026.
Fiscal third-quarter equipment book-to-bill reached 1.27, while fiscal 2026 revenue growth guidance is 3.50-4.00 percent.
Siemens Healthineers stock costs EUR 41.62 at Lang & Schwarz on October 21, 2026 at 4:42 p.m. CEST, 0.43 percent above the Xetra close of October 20, 2026 at EUR 41.44.
Fourth-quarter results and the analyst call are scheduled for November 5, 2026.

3D-Architekturrender eines modernen Glas-Bürogebäudes mit Grünanlagen — Siemens Healthineers DE000SHL1006 illustriert modernes Architektur-Render eines unmarkierten Glas-Bürocampus mit gepflegten Grünflächen und Platz, Illustration mit AI erstellt.

Siemens Healthineers (ISIN DE000SHL1006) is valued at EUR 41.62 at Lang & Schwarz on October 21, 2026 at 4:42 p.m. CEST, up 0.43 percent versus the Xetra close of October 20, 2026 at EUR 41.44. On October 15, 2026, RBC raised its price target from EUR 45.00 to EUR 48.00 and kept its Outperform rating, according to MarketScreener.

RBC target reaches EUR 48

The new target lies 15.33 percent above the Lang & Schwarz price. RBC linked its revised view to the launch of Accela, a new radiation therapy system, while the research note retained the Outperform rating.

Third-quarter orders showed strength

Siemens Healthineers reported an equipment book-to-bill ratio of 1.27 in fiscal third quarter 2026. The core Imaging and Precision Therapy businesses grew 5.00 percent in the quarter, while Precision Therapy grew 9.00 percent, according to the Q3 earnings-call transcript carried by Yahoo Finance.

What does the EUR 48 target imply?

The company lowered fiscal 2026 revenue growth guidance from 4.50-5.00 percent to 3.50-4.00 percent in the Q3 update. Adjusted earnings per share guidance was raised by EUR 0.15 to a range of EUR 2.35-2.45, with tariff refunds accounting for the increase, according to the same transcript.

Dates and valuation

The investor-relations calendar lists fourth-quarter results and the analyst call for November 5, 2026, followed by a US roadshow on November 6, 2026, according to Siemens Healthineers. The stock's price-to-earnings ratio is 21.03, while its 52-week range is EUR 32.81 to EUR 49.71 as of October 21, 2026.

Stock remains below its yearly high

At EUR 41.62, the stock is 16.28 percent below its 52-week high of EUR 49.71 and 26.84 percent above its 52-week low of EUR 32.81. The current market capitalization is EUR 46.6 billion as of October 21, 2026.

At Lang & Schwarz, Siemens Healthineers was trading at EUR 41.62 on October 21, 2026 at 4:42 p.m. CEST, plus 0.43 percent versus the Xetra close of October 20, 2026 at EUR 41.44. The further course of trading is shown by the continuously updated real-time quote of Siemens Healthineers stock.